HRTS 📈 Tema Cardiovascular and - Overview
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • • Health
HRTS: GLP-1, Cardiovascular, Metabolic, Diabetes, Obesity, Heart
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
Additional Sources for HRTS ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HRTS ETF Overview
| Market Cap in USD | 81m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2023-11-20 |
HRTS ETF Ratings
| Growth 5y | 42.5% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -93.7 |
| Analysts | - |
| Fair Price Momentum | 24.36 USD |
| Fair Price DCF | - |
HRTS Dividends
No Dividends PaidHRTS Growth Ratios
| Growth Correlation 3m | -76.4% |
| Growth Correlation 12m | 28.7% |
| Growth Correlation 5y | 44.5% |
| CAGR 5y | 10.15% |
| CAGR/Mean DD 5y | 1.98 |
| Sharpe Ratio 12m | -0.22 |
| Alpha | -29.29 |
| Beta | 1.07 |
| Volatility | 24.93% |
| Current Volume | 10k |
| Average Volume 20d | 18.3k |
What is the price of HRTS stocks?
As of December 22, 2024, the stock is trading at USD 29.15 with a total of 10,000 shares traded.
Over the past week, the price has changed by -4.21%, over one month by -4.22%, over three months by -14.71% and over the past year by +1.85%.
As of December 22, 2024, the stock is trading at USD 29.15 with a total of 10,000 shares traded.
Over the past week, the price has changed by -4.21%, over one month by -4.22%, over three months by -14.71% and over the past year by +1.85%.
Is Tema Cardiovascular and a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Tema Cardiovascular and (NASDAQ:HRTS) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 42.51 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HRTS as of December 2024 is 24.36. This means that HRTS is currently overvalued and has a potential downside of -16.43%.
Partly, yes. Based on ValueRay Analyses, Tema Cardiovascular and (NASDAQ:HRTS) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 42.51 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HRTS as of December 2024 is 24.36. This means that HRTS is currently overvalued and has a potential downside of -16.43%.
Is HRTS a buy, sell or hold?
Tema Cardiovascular and has no consensus analysts rating.
Tema Cardiovascular and has no consensus analysts rating.
What are the forecast for HRTS stock price target?
According to ValueRays Forecast Model, HRTS Tema Cardiovascular and will be worth about 27.2 in December 2025. The stock is currently trading at 29.15. This means that the stock has a potential downside of -6.86%.
According to ValueRays Forecast Model, HRTS Tema Cardiovascular and will be worth about 27.2 in December 2025. The stock is currently trading at 29.15. This means that the stock has a potential downside of -6.86%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 27.2 | -6.9% |